TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: The pivotal ALCANZA phase III trial demonstrated significantly superior efficacy of BV over physician’s choice (methotrexate or bexarotene) in patients with CD30-positive CTCL, including MF and pcALCL, with higher ORR4 and improved quality of life.